Upgrade to premium to see the full reasoning behind each conviction change.
Sign in to unlockFair Value Distribution — percentile bands
100.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
1.0%/yr
±12.6% · revenue growth to justify current price
FCF-Based Reverse DCF
7.1%/yr
±3.5% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockNo analysis yet
No analysis yet
HUM faces material headwinds from 2025 Star Rating decline (lawsuit outcome pending Fifth Circuit appeal), expanding RADV audit exposure for PY2018-2024, and Florida Medicare concentration (14% of rev...